Compare Novartis AG (NVS) vs Wynn Resorts, Limited (WYNN) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, amid mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, though U.S. margins face pressure. Revenue reached $7.14B in 2025 with a net income margin of 4.58%, while debt remains elevated at $10.5B. Recent institutional buying includes Barrow Hanley's $321M investment, and analysts maintain a bullish consensus price target of $132.44.

Wynn's outlook is supported by Macau recovery and new project pipelines like Wynn Al Marjan, but high capital expenditure and debt load pose risks. The stock offers 44% upside to consensus target, though investors should monitor margin pressures and capex execution. Near-term support lies at $91, with resistance at $93.